Published:
PDL BioPharma Announces Investor Conference Call Today
Call to Be Held on August 19 at 5 p.m. ET
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI)
will hold an investor conference call and webcast today at 5:00 p.m.
Eastern time following today's announcement of a collaboration agreement
with Bristol-Myers Squibb Company for the co-development and
commercialization of elotuzumab, PDL's phase 1 antibody candidate for
multiple myeloma, and an option, exercisable by Bristol-Myers Squibb, to
expand the collaboration to include PDL241, a preclinical antibody
candidate for immunologic indications. The company plans to discuss this
collaboration as well as provide an update on company activities.
A webcast of the conference call will be available through the PDL website:
www.pdl.com. Please connect to this website at least 15 minutes prior to
the webcast to allow time for any software download that may be needed to
hear the webcast. Financial and statistical information to be discussed
during the call will be available on the PDL website. A replay will be
available at www.pdl.com starting approximately one hour after completion
of the webcast.
An audio replay will also be available by telephone from approximately 7:00
p.m. Eastern time on August 19, 2008 through 7:00 p.m. Eastern time on
September 19, 2008. To access the replay, dial 1-800-642-1687 from inside
the U.S. and 706-645-9291 from outside the U.S.; enter conference ID number
60869076.
About PDL BioPharma
PDL BioPharma, Inc. is a biotechnology company focused on the discovery and
development of novel antibodies in oncology and immunologic diseases. For
more information, please visit www.pdl.com.
NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of
PDL.
Copyright © 2009, MarketWire
Copyright © 2009, NewsBlaze,
Daily NewsTags: ,Pharmaceuticals and Biotech:Biotech, PharmaceuticalsandBiotech:Drugs, PharmaceuticalsandBiotech:EquipmentandSupplies, PharmaceuticalsandBiotech:Trials, ,NASDAQ01,NASDAQ01,CA,REDWOOD CITY, CA
Search News
Daily News
